高级检索
    冯喆, 张剑, 李文桦, 胡夕春, 郭丽萍. 术前应用HER2特异性树突状细胞疫苗治疗导管原位癌患者的安全性和有效性评估[J]. 循证医学, 2018, 18(3): 137-139. DOI: 10.12019/j.issn.1671-5144.2018.03.003
    引用本文: 冯喆, 张剑, 李文桦, 胡夕春, 郭丽萍. 术前应用HER2特异性树突状细胞疫苗治疗导管原位癌患者的安全性和有效性评估[J]. 循证医学, 2018, 18(3): 137-139. DOI: 10.12019/j.issn.1671-5144.2018.03.003
    shu
    FENG Zhe, ZHANG Jian, LI Wen-hua, HU Xi-chun, GUO Li-ping. Safety and Efficacy Evaluation of HER2 Peptide-Pulsed Dendritic Cell Vaccine in Preoperative Treatment of Patients with HER2pos Ductal Carcinoma in Situ[J]. Journal of Evidence-Based Medicine, 2018, 18(3): 137-139. DOI: 10.12019/j.issn.1671-5144.2018.03.003
    Citation: FENG Zhe, ZHANG Jian, LI Wen-hua, HU Xi-chun, GUO Li-ping. Safety and Efficacy Evaluation of HER2 Peptide-Pulsed Dendritic Cell Vaccine in Preoperative Treatment of Patients with HER2pos Ductal Carcinoma in Situ[J]. Journal of Evidence-Based Medicine, 2018, 18(3): 137-139. DOI: 10.12019/j.issn.1671-5144.2018.03.003
    shu

    术前应用HER2特异性树突状细胞疫苗治疗导管原位癌患者的安全性和有效性评估

    Safety and Efficacy Evaluation of HER2 Peptide-Pulsed Dendritic Cell Vaccine in Preoperative Treatment of Patients with HER2pos Ductal Carcinoma in Situ

      摘要
      • HTML全文
      • 参考文献(14)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回